GoldenGolden
Advanced Search
Mammoth Biosciences

Mammoth Biosciences

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics.

Mammoth Biosciences is an American company based in San Francisco founded on June 1, 2017. Mammoth Biosciences uses CRISPR technology to develop bio-sensing technologies for diagnostics in industries such as healthcare, agriculture, manufacturing, and forensics. Their CRISPR platform utilizes two CRISPR proteins: Cas12 and Cas13. The technology being used by Mammoth Bioscience theoretically allows for the detection of any biomarker and/or disease that contains either RNA and/or DNA.

Products and services
Point of care strip

Mammoth biosciences uses technology licensed from UC Berkley and has created a credit card strip capable of delivering health diagnostics at the point of care in hospital and home settings. Their diagnostic strip works by dropping the desired fluid sample onto the strip and waiting for panels on the strip to change colour indicating the test is complete. The CRISPR technology is embedded within the strip, and if or when the desired reaction takes place a coloured molecule is released called a reporter molecule. Different reporter molecules can be present and eventually build up into colours that can be seen with the naked eye. The user then takes a photo of the strip after the reaction is complete (approximately taking 30 minutes) using a smart phone application developed my Mammoth Biosciences. Users can see the results of their strip test using the app.

Coronavirus diagnostic

Mammoth Biosciences is partnering with UC San Francisco to develop a diagnostic test to identify people infected with coronavirus, SARS-CoV-2 (previously called 2019-nCoV). The new coronavirus strain, identified December 31, 2019 is responsible for an outbreak of disease called COVID-19 that began in Wuhan, China in December, 2019 and was declared a global emergency by the World Health Organization (WHO). For current testing samples are shipped to the Centers for Disease Control and Prevention where the test can take six or more hours to complete. The test being developed by Mammoth Biosciences is expected to take one or two hours and be completed at the doctor’s office. The test would involve a nasal swab being placed in a tube with the CRISPR-Cas system and using a color-changing strip of paper to check for a positive or negative test result. Their test, uses CRISPR-Cas12a-based lateral flow assay and RT-LAMP technology and gives results in less than 40 minutes was validated in patient respiratory swab RNA extracts and results were published in April, 2020.

Funding

Mammoth Biosciences has received a disclosed amount of $23min venture capital funding from Mayfield, NFX, 8VC, AME Cloud, Wireframe, Kairos, and Boom Capital.

Timeline

September 9, 2021
Mammoth Biosciences raises $45,000,000 in a series C and $150,000,000 million in a series D funding round, from various backers, including Redmile Group, Foresiter Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, NFX, Plum Alley, and Amazon.
March 8, 2021
Mammoth Biosciences announces that it has been named by Fierce Medtech as one of 2020's Fierce 15, designating it as one of the most promising private companies in the industry.
January 28, 2021
Mammoth Biosciences, Inc. announced a co-marketing agreement with Agilent Technologies to support the anticipated launch of a complete CRISPR-based SARS-CoV-2 diagnostic solution.
January 30, 2020
Mammoth Biosciences raises a $45,000,000 series B round from Decheng Capital.
August 2018
Mammoth Biosciences raises a $23,000,000 series A round from 8VC and NFX.
May 2017
Mammoth Biosciences raises a $120,000 seed round from 8VC, AME Cloud Ventures, NFX and Wireframe Ventures.

Funding rounds

Patents

Products

People

Name
Role
LinkedIn

Andy Lane

Ashley Tehran

Ashley Tehranchi

Founder

Celestine

Investor

James Broughton

Further reading

Title
Author
Link
Type
Date

After gene-editing, Crispr’s new frontier to detect diseases is closer to becoming a reality

Akshat Rathi

At-home CRISPR kit will diagnose you better than WebMD

Kristin Houser

Jennifer Doudna's latest CRISPR company debuts

Sharon Begley

New startup promises ‘world’s first’ CRISPR-powered disease detection

Dyllan Furness

Xconomy: Home Tests in Mind, Doudna Startup Races Rivals in CRISPR Diagnostics

Alex Lash

Documentaries, videos and podcasts

Title
Date
Link

Mammoth Biosciences launches a CRISPR-powered search engine for disease detection

April 26, 2018

The Mammoth CRISPR Platform

April 26, 2018

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Gené Teare
September 9, 2021
Crunchbase News
San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.
Emma Betuel
September 9, 2021
TechCrunch
The CRISPR-based biotech startup Mammoth Biosciences is officially a unicorn, the company says. The billion dollar valuation comes on the back of a $150 million series D round led by Redmile Group, with participation from Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, Plum Alley and NFX. Combined with a late [...]
Amirah Al Idrus
September 9, 2021
FierceBiotech
On the back of a busy year, Mammoth Biosciences is getting a $195 million boost, which will ramp up the development of its gene-editing pipeline, as well as fuel its work in CRISPR-based diagnostics.
Alexandra Ames
August 17, 2021
TechCrunch
Solving the twin challenges of human and planetary health is the greatest task of our generation, and it also presents the greatest entrepreneurial opportunity in history which is why we've partnered with Mayfield to bring you an engineering biology track to Disrupt 2021 this September 21-23. Haven't secured your spot yet? Grab your ticket now [...]
July 21, 2021
WebWire
VSC, an independent communications firm that has supported more than 475 startups with 50 exits and three IPOs, announced today that three of its longtime executives -- Maggie Philbin, Anne Sophie Hurst and Eric Gonzalez -- have been promoted to Partner. "It's a dream team," said Vijay Chattha, CEO at VSC, who founded the firm 18 years ago. "While many firms churn through senior teams and focus on new blood, we have promoted from within and the firm and its culture is a reflection of th...
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.